News
TXMD
2.290
+4.57%
0.100
TherapeuticsMD Inc. Stock Rallies 4.6%, Outperforms Market
Dow Jones · 6d ago
Weekly Report: what happened at TXMD last week (0126-0130)?
Weekly Report · 6d ago
TherapeuticsMD Inc. Stock Slips 6.1%, Underperforms Market
Dow Jones · 01/30 21:34
TherapeuticsMD Inc. Stock Climbs 7.5%, Outperforms Market
Dow Jones · 01/29 21:34
TherapeuticsMD Inc. Stock Slides 11.6%, Underperforms Market
Dow Jones · 01/28 21:32
TherapeuticsMD Inc. Stock Slides 12.6%, Underperforms Market
Dow Jones · 01/27 21:32
TherapeuticsMD Inc. Stock Advances 6.1%, Outperforms Market
Dow Jones · 01/26 21:32
Weekly Report: what happened at TXMD last week (0119-0123)?
Weekly Report · 01/26 10:07
Weekly Report: what happened at TXMD last week (0112-0116)?
Weekly Report · 01/19 10:12
TherapeuticsMD Inc. Stock Climbs 4.7%, Outperforms Market
Dow Jones · 01/15 21:34
TherapeuticsMD Inc. Stock Sheds 3.7%, Underperforms Market
Dow Jones · 01/12 21:35
Weekly Report: what happened at TXMD last week (0105-0109)?
Weekly Report · 01/12 10:12
TherapeuticsMD Inc. Stock Rallies 4.9%, Outperforms Market
Dow Jones · 01/09 21:34
After-Hours Gainers: ALXO, GMED, ACRV, And Biotech Peers Rally On Trial Data And Earnings Updates
NASDAQ · 01/08 03:14
TherapeuticsMD Inc. Stock Rallies 13.3%, Outperforms Market
Dow Jones · 01/06 21:32
TherapeuticsMD Inc. Stock Advances 9.1%, Outperforms Market
Dow Jones · 01/05 21:32
Weekly Report: what happened at TXMD last week (1229-0102)?
Weekly Report · 01/05 10:06
TherapeuticsMD Inc. Stock Falls 2.4%, Underperforms Market
Dow Jones · 12/30/2025 21:34
TherapeuticsMD Insider Makes Bold Move With New Stock Purchase
TipRanks · 12/30/2025 02:05
TherapeuticsMD Inc. Stock Slips 3.4%, Underperforms Market
Dow Jones · 12/29/2025 21:34
More
Webull provides a variety of real-time TXMD stock news. You can receive the latest news about Therapeuticsmd Inc through multiple platforms. This information may help you make smarter investment decisions.
About TXMD
TherapeuticsMD, Inc. is a pharmaceutical royalty company, which primarily collects royalties from its licensees. It receives royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. It granted a license to commercialize IMVEXXY, BIJUVA, and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands and assigned its exclusive license to commercialize ANNOVERA to Mayne Pharma. IMVEXXY (estradiol vaginal inserts) pharmaceutical product is for the treatment of moderate-to-severe dyspareunia. BIJUVA pharmaceutical product is a Food and Drug Administration (FDA)-approved bioidentical hormone therapy combination of estradiol and progesterone in a single, oral capsule for the treatment of moderate-to-severe vasomotor symptoms due to menopause in women with a uterus. ANNOVERA pharmaceutical product is a one-year ring-shaped contraceptive vaginal system (CVS).